VivoSeq
Other

Islet Cell Transplantation

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Islet Cell Transplantation is an early-stage landscape with 0 programs across 1 company. The most active players are Anelixis Therapeutics, LLC.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

60/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Anelixis Therapeutics, LLC

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed3 · 50%
Withdrawn1 · 17%
Terminated1 · 17%
Active, not recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Allogenic Islet Cell Transplantation
Active, not recruiting·UUniversity of Chicago·Phase 1/2·NCT00160732·50 enrolled
Pancreatic Islet Cell Transplantation
Completed·—·Phase 1·NCT00214786·4 enrolled
Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment
Completed·—·Phase 1·NCT00530686·1 enrolled
Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation
Completed·—·Phase 2·NCT00315627·3 enrolled
Nitrite Infusion in Islet Cell Transplantation
Terminated·UUniversity of Alabama at Birmingham·Phase 2·NCT03544242·4 enrolled
Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation
Withdrawn·AAnelixis Therapeutics, LLC·Phase 2·NCT04711226

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)